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Volume 49, Number 2 Lee 433was superior to treatment with single sclerosing agents and
further study is warranted.
CONCLUSION
Intralesional hemorrhage in VMs is uncommon. Accu-
rate diagnosis and differential diagnosis should be based on
the history, clinical presentations, diagnositic needle aspi-
ration, and MRI findings. Percutaneous absolute ethanol
and Bleomycin A5 embolosclerotherapy is a safe and effec-
tive treatment of choice.
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In this article, the authors describe the successful management
of 16 patients with relatively sudden enlargement of a venous
malformation (VM) due to acute hemorrhage. This represents a
small subset of patients with VMs since the majority of VMs do not
develop intra-lesion hemorrhage. The authors report good results
using a combination of ethanol and bleomycin as the sclerosing
agent. While the use of the powerful sclerosing agent absolute
ethanol is quite well accepted for treating more aggressive arterio-
venous malformations, its use in VM is more limited. This is
because of serious potential complications reported with its use,
including acute complications of nerve palsy or even cardiopulmo-
nary arrest.1,2 Therefore, many have begun to consider the use of
less dangerous sclerosing agents, such as detergent-based foam,
especially for less aggressive VMs, including those with transder-
mal extension in which there is a higher risk for complications from
ethanol injection. Although foam sclerotherapy is likely less effec-
tive than ethanol, the complication rate is lower, and if VMs recur,
or are only partially treated initially, they can be re-treated withThe authors attempted to reduce the risk involved with etha-
nol injection of the VM by mixing it with bleomycin. However, it
is difficult to judge the contribution of bleomycin to the overall
treatment outcome since the ethanol was given first to block the
draining veins; regardless of its amount, there is substantial risk of
the vascular spasm induced by the ethanol before bleomycin begins
to work, reducing its effective contact with the endothelial cells.
Bleomycin was used extensively to various lymphatic malfor-
mations (LMs) with excellent result for the macrocystic lesions in
particular.3,4 It still remains a major option when OK-432 (Chugai
Pharmaceutical, Tokyo, Japan), also known as picibanil, which is
made with attenuated streptococcal exotoxin, is not available for
the LM.5,6 However, we have found bleomycin is generally less
effective when the LM is mixed with the VM. Furthermore, the
potential concern for pulmonary fibrosis as a long-term complica-
tion of bleomycin remains to be answered especially when it is
injected to the VM/venous system. This potential long-term con-
cern has led us not to use bleomycin for VM treatment.
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without acute side effects using a combination of ethanol and
bleomycin for treating acute hemorrhage within VMs, I believe
that foam sclerotherapy should be the sclerosing agent used in
these cases, in order to reduce potential complications, accepting a
higher recurrence rate with the knowledge that the VM can be
retreated.7,8
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